Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Integral Consulting (United States)
InstitutionResearch output, impact & collaborations
Integral Consulting (United States) is a research organisation in Seattle, US. OpenAlex records 2,774 works and 21,961 citations for it. 1,192 researchers list it as their most recent affiliation.
2,774
Works
21,961
Citations
1,192
Researchers
60
Avg h-index
How has Integral Consulting (United States)'s publication output changed over time?
ScholarIQpublication output · 2015–2021
Output grew100% over the shown period — from 1 works in 2015 to 2 in 2021.
1
2
4
1
1
1
2
2015201620172018201920202021
Who are the most-cited researchers behind Integral Consulting (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Integral Consulting (United States)?
ScholarIQmost cited works
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, Lisa A. Beck, Andrew Blauvelt, Michael J. Cork, Jonathan I. Silverberg, Mette Deleuran, Yoko Kataoka, J.‐P. Lacour, Külli Kingo, Margitta Worm, Yves Poulin, Andreas Wollenberg, Yuhwen Soo, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, Heribert Staudinger, Vera Mastey, Laurent Eckert, Abhijit Gadkari, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu
New England Journal of Medicine. 20162,067 CitationsOPEN ACCESS
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
The Lancet. 20171,258 CitationsOPEN ACCESS
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball
S58727509. 2017884 CitationsOPEN ACCESS
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi
New England Journal of Medicine. 2016845 CitationsOPEN ACCESS
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez
The Lancet. 2018669 Citations
How much of the research on Integral Consulting (United States) is open access?
ScholarIQopen access share
67%OPEN ACCESS
Gold
8%
Green
8%
Hybrid
25%
Bronze
25%
Closed
33%